ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.95
0.34%
US Tech 100
17,402.60
1.91%
S&P 500
5,107.49
0.85%
US Dollar vs CAD
1.36757
0.06%
Bitcoin
61,650.47
4.28%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hikma Pharmaceuticals Plc (HIK)

  7. Hikma Pharmaceuticals Plc (HIK) News

HIK

Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals Plc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:HIK
DateTimeSourceHeadlineSymbolCompany
04/25/20248:28AMRNS Regulatory NewsHikma Pharmaceuticals Plc Result of AGMLSE:HIKHikma Pharmaceuticals Plc
04/25/20244:15AMAlliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
04/25/20244:15AMAlliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
04/25/20241:00AMRNS Regulatory NewsHikma Pharmaceuticals Plc Trading StatementLSE:HIKHikma Pharmaceuticals Plc
04/17/20244:42AMRNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
04/15/202410:43AMRNS Regulatory NewsHikma Pharmaceuticals Plc Hikma appoints new President of Generics businessLSE:HIKHikma Pharmaceuticals Plc
04/11/20244:58AMRNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
04/02/20243:50AMRNS Regulatory NewsHikma Pharmaceuticals Plc Block listing Interim ReviewLSE:HIKHikma Pharmaceuticals Plc
03/22/20244:21AMRNS Regulatory NewsHikma Pharmaceuticals Plc Annual Financial Report and Notice of AGMLSE:HIKHikma Pharmaceuticals Plc
03/13/20244:42AMRNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
03/07/20247:52AMRNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
03/01/20244:17AMRNS Regulatory NewsHikma Pharmaceuticals Plc Total Voting RightsLSE:HIKHikma Pharmaceuticals Plc
02/22/20243:42AMAlliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
02/22/20243:42AMAlliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
02/22/20241:09AMAlliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:09AMAlliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:08AMAlliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
02/22/20241:08AMAlliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
02/22/20241:08AMAlliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
02/22/20241:08AMAlliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
02/22/20241:07AMAlliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:07AMAlliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:06AMAlliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:06AMAlliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:06AMAlliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:06AMAlliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:05AMAlliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:05AMAlliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
02/22/20241:00AMRNS Regulatory NewsHikma Pharmaceuticals Plc Final ResultsLSE:HIKHikma Pharmaceuticals Plc
02/21/202412:20PMUK RegulatoryHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityLSE:HIKHikma Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HIK

Your Recent History

NASDAQ
JAGX
Jaguar Health
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
GDVM
Global Developments (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
SPZI
Spooz (PK)
USOTC
BEGI
BlackStar Enterprise (PK)
NASDAQ
HOLO
MicroCloud Hologram
NASDAQ
AMRN
Amarin
USOTC
SHMP
NaturalShrimp (QB)
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
MONI
Moon Equity (PK)
USOTC
RDGL
Vivos (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
BLLB
Bell Buckle (PK)
USOTC
ACRL
Atacama Resources (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved